title: SARS vaccine development.
abstract: Developing effective and safe vaccines is urgently needed to prevent infection by severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV). The inactivated SARS-CoV vaccine may be the first one available for clinical use because it is easy to generate; however, safety is the main concern. The spike (S) protein of SARS-CoV is the major inducer of neutralizing antibodies, and the receptor-binding domain (RBD) in the S1 subunit of S protein contains multiple conformational neutralizing epitopes. This suggests that recombinant proteins containing RBD and vectors encoding the RBD sequence can be used to develop safe and effective SARS vaccines.
authors: New York Blood Center, New York, New York 10021, USA. SJiang@NYBloodcenter.org
authors: Shibo
authors: S
authors: Jiang
authors: Yuxian
authors: Y
authors: He
authors: Shuwen
authors: S
authors: Liu
mesh_terms: D000939:Epitopes; D006801:Humans; D008562:Membrane Glycoproteins / Q000276:immunology; D045473:Severe acute respiratory syndrome-related coronavirus / Q000276:immunology*; D045169:Severe Acute Respiratory Syndrome / Q000517:prevention & control*; D064370:Spike Glycoprotein, Coronavirus; D015164:Vaccines, Inactivated; D014759:Viral Envelope Proteins / Q000276:immunology; D014765:Viral Vaccines
chemical_list: D000939:Epitopes; D008562:Membrane Glycoproteins; D064370:Spike Glycoprotein, Coronavirus; D015164:Vaccines, Inactivated; D014759:Viral Envelope Proteins; D014765:Viral Vaccines; C578557:spike glycoprotein, SARS-CoV; C578553:spike protein, mouse hepatitis virus